[Simard J, Dumont M, Labuda, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer. 2003; 10(2): 225-259.10.1677/erc.0.0100225]Search in Google Scholar
[Takaku H, Minagawa W, Takagi M, Nashimot M. The N-terminal half-domain of the long form of tRNase Z is required for the Rnase 65 activity. Nucleic Acids Res. 2004; 32(15): 4429-4438.10.1093/nar/gkh774]Search in Google Scholar
[Kover W, Guevara C, Chen, Y. Neuteboom S, Bookstein R, Tavtigian S, Lees E. The product of candidate prostate cancer susceptibility gene ELAC2 interacts with the γ-tubulin complex. Int. J Cancer. 2003; 104(3): 283-288.]Search in Google Scholar
[Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin A, Nathanson KL, Wein AJ, Malkowicz B. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 2000; 67(4): 1010-1019.10.1086/303096]Search in Google Scholar
[Thigpen AE, Cala KM, Russell DW. Characterization of Chinese hamster ovary cell lines expressing human steroid 5α-reductase isozymes. J Biol Chem. 1993; 268 (23): 17404-17412.10.1016/S0021-9258(19)85349-8]Search in Google Scholar
[Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995; 55(18): 3973-3975.]Search in Google Scholar
[Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JKV. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 1997; 57(6): 1020-1022.]Search in Google Scholar
[Labrie F, Sagimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N. Structure of human type II 5α-reductase gene. Endocrinology. 1992; 131(3): 1571-1573.10.1210/endo.131.3.15054841505484]Search in Google Scholar
[Jaffe JM, Malkowicz B, Walker AH, MacBride S, Peschel R, Tomaszewski J, Arsdalen KV, Wein AJ, Rebbeck TR. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 2000; 60(6): 1626-1630.]Search in Google Scholar
[Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215.10.1093/nar/16.3.12153347653344216]Search in Google Scholar
[Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate. 2004; 59(1): 69-76.10.1002/pros.1035814991867]Search in Google Scholar
[Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu J, Feng Z, Ostrander EA. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study. Cancer Epidemiol Biomarkers Prev. 2003; 12(9): 876-881.]Search in Google Scholar
[Camp NJ, Swensen J, Horne BD, Farnham JM, Thomas A, Cannon-Albright LA, Tavtigian SV. Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and famlial early-onset prostate cancer. Genet Epidemiol. 2005; 28(3): 232-243.10.1002/gepi.2005415593091]Search in Google Scholar
[Meitz JC, Edwards SM, Easton DF, Murkin A, Ardern-Jones A, Jackson RA, Williams S, Dearnaley DP, Stratton MR, Houlston RS. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis age of onset of disease. Br J Cancer. 2002; 87(8): 905-908.10.1038/sj.bjc.6600564237617912373607]Search in Google Scholar
[Adler D, Kanji N, Trpkoy K, Fick G, Hughes RM. HPC2/ELAC2 gene variants associated with incident prostate cancer. J Hum Genet. 2003; 48(12): 634-638.10.1007/s10038-003-0091-614625808]Search in Google Scholar
[Rökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TLJ, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res. 2001; 61(16): 6038-6041.]Search in Google Scholar
[Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schald DJ, Thibodeau SN. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 2001; 61(17): 6494-6499.]Search in Google Scholar
[Vesprini D, Nam RK, Trachtenberg J, Jewett MAS, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet. 2001; 68(4): 912-917.10.1086/319502]Search in Google Scholar
[Yokomizo A, Koga H, Kinukawa N, Tsukamoto T, Hirao Y, Akaza H, Mori M, Naito S. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate. 2004; 61(3): 248-252.10.1002/pros.20107]Search in Google Scholar
[Makridakis NM, Reichardt JK. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev. 2001; 23(1): 24-29.10.1093/oxfordjournals.epirev.a000791]Search in Google Scholar
[Latil AG, Azzouzi R, Cancel GS, Gulllaume EC, Cochan-Priollet C, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 2001; 92(5): 1130-1137.10.1002/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-B]Search in Google Scholar
[Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JKV. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2001; 10(10): 1077-1082.]Search in Google Scholar
[Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H. The association of 5α-reductase type II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 2007; 26(2): 100-107.10.1089/dna.2006.0534]Search in Google Scholar
[Nam RK, Toi A, Vesprini D, Ho M, Sweet J, Trachtenberg J, Jewett MAS, Narod SA. V89L polymorphism of type-2, 5α-reductase enzyme gene predicts prostate cancer presence and progression. Urology. 2001; 57 (1): 199-204.10.1016/S0090-4295(00)00928-6]Search in Google Scholar
[Neslund-Dudas C, Bock CH, Monaghan K, Nock NL, Yang JJ, Rundle A, Tang D, Rybicki BA. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate. 2007; 67(15): 1654-1663.10.1002/pros.20625]Search in Google Scholar
[Li Z, Habuchi T, Mitsumori K, Kamoto T, Kinoshitu H, Segawa T, Ogava O, Kato T. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol. 2003; 169(6): 2378-2381.10.1097/01.ju.0000056152.57018.31]Search in Google Scholar
[Rajender S, Vuayalakshmi K, Pooja S, Madhavi S, Paul SFD, Vettriselvi V, Shroff S, Singh L, Thangaraj K. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl. 2009; 30(6): 703-710.10.2164/jandrol.108.007377]Search in Google Scholar
[Soderstrom TG, Bjelfman C, Brekkan E, Ask B, Egevad L, Norlen BJ, Rane A. Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab. 2001; 86(2): 855-858.]Search in Google Scholar